Astrana Health (ASTH) saw its stock plummet 12.05% in intraday trading on Friday, following the company's disappointing fourth-quarter 2024 results and lackluster guidance for 2025.
Despite an 88.4% year-over-year increase in revenue to $665.21 million, the healthcare provider missed Wall Street's expectations. The company reported an adjusted loss of $0.15 per share, falling short of analysts' estimates of $0.12 earnings per share.
Astrana Health's outlook for 2025 also failed to impress investors. The company forecasted revenue in the range of $2.5 billion to $2.7 billion and adjusted EBITDA of $170 million to $190 million, both lower than analysts' projections. The weaker guidance was attributed to headwinds from higher-than-expected Medicaid trends and costs associated with strategic investments in integration, automation, and AI.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.